155 related articles for article (PubMed ID: 9052470)
1. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines.
Kreis W; Budman DR; Calabro A
Br J Urol; 1997 Feb; 79(2):196-202. PubMed ID: 9052470
[TBL] [Abstract][Full Text] [Related]
2. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro.
Budman DR; Calabro A; Kreis W
Anticancer Drugs; 2002 Nov; 13(10):1011-6. PubMed ID: 12439335
[TBL] [Abstract][Full Text] [Related]
3. Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
Arah IN; Dixon SC; Horti J; Figg WD
Neoplasma; 1999; 46(2):117-23. PubMed ID: 10466436
[TBL] [Abstract][Full Text] [Related]
4. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
Kübler HR; van Randenborgh H; Treiber U; Wutzler S; Battistel C; Lehmer A; Wagenpfeil S; Hartung R; Paul R
Prostate; 2005 Jun; 63(4):385-94. PubMed ID: 15617027
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect of estramustine and [3'-keto-Bmtl]-[Val2]-cyclosporine (PSC 833) on the inhibition of androgen receptor phosphorylation in LNCaP cells.
Wang LG; Liu XM; Budman DR; Kreis W
Biochem Pharmacol; 1999 Oct; 58(7):1115-21. PubMed ID: 10484069
[TBL] [Abstract][Full Text] [Related]
6. The use of estramustine phosphate in the modern management of advanced prostate cancer.
Ravery V; Fizazi K; Oudard S; Drouet L; Eymard JC; Culine S; Gravis G; Hennequin C; Zerbib M
BJU Int; 2011 Dec; 108(11):1782-6. PubMed ID: 21756277
[TBL] [Abstract][Full Text] [Related]
7. Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.
Burich RA; Holland WS; Vinall RL; Tepper C; White RW; Mack PC
BJU Int; 2008 Nov; 102(10):1458-66. PubMed ID: 18565171
[TBL] [Abstract][Full Text] [Related]
8. Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study.
Williams JF; Muenchen HJ; Kamradt JM; Korenchuk S; Pienta KJ
Prostate; 2000 Sep; 44(4):275-8. PubMed ID: 10951491
[TBL] [Abstract][Full Text] [Related]
9. A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents.
Kreis W; Budman DR; Calabro A
Cancer Chemother Pharmacol; 2001; 47(1):78-82. PubMed ID: 11221966
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
Urology; 2003 Apr; 61(4):774-80. PubMed ID: 12670564
[TBL] [Abstract][Full Text] [Related]
11. Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
Kreis W; Budman D
Semin Oncol; 1999 Oct; 26(5 Suppl 17):34-8. PubMed ID: 10604267
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Pienta KJ; Smith DC
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
[TBL] [Abstract][Full Text] [Related]
14. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
[TBL] [Abstract][Full Text] [Related]
15. A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.
Dahmani A; de Plater L; Guyader C; Fontaine JJ; Berniard A; Assayag F; Beuzeboc P; Marangoni E; Némati F; Poupon MF; Pasik C; Oudard S; Decaudin D
Anticancer Drugs; 2010 Nov; 21(10):927-31. PubMed ID: 20827173
[TBL] [Abstract][Full Text] [Related]
16. Estramustine-based chemotherapy.
Hudes G
Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells.
Li Y; Hong X; Hussain M; Sarkar SH; Li R; Sarkar FH
Mol Cancer Ther; 2005 Mar; 4(3):389-98. PubMed ID: 15767548
[TBL] [Abstract][Full Text] [Related]
18. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Petrylak DP
Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
[TBL] [Abstract][Full Text] [Related]
20. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
